Spyre Therapeutics, Inc. SYRE
85.69
(1.40)
(1.61%)
as of 25 Sep
- Market cap
- $7.7B
- P/E
- 0.0×
Follow SYRE
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — | — |
P/S ratio |
9.67 | 15.64 | 23.52 | — | — | 14.79 | 15.24 | 140.04 | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — | — |
P/Operating CF |
(10.28) | (13.86) | (21.66) | — | — | (16.21) | (1.96) | (4.76) | — | — |
P/B ratio |
0.71 | 1.62 | 2.31 | — | — | 3.72 | 0.71 | 0.00 | — | — |
Price to Tangible BV |
0.71 | 1.62 | 2.31 | — | — | 3.72 | 0.71 | 0.00 | — | — |
EV/Sales |
(4.05) | 5.97 | 12.28 | — | — | 10.38 | (8.68) | (181.86) | — | — |
EV/EBITDA |
0.87 | 0.00 | 0.00 | — | — | 0.00 | 0.24 | 0.79 | — | — |
EV/Operating CF |
1.00 | (1.26) | (2.53) | — | — | (4.08) | 0.25 | 1.92 | — | — |
EV/FCF |
0.98 | (1.23) | (2.50) | — | — | (4.04) | 0.25 | 1.93 | — | — |
Quick Ratio |
16.32 | 9.48 | 7.31 | 3.92 | 8.90 | 4.66 | 3.83 | 10.61 | 11.16 | 12.89 |
Current Ratio |
16.75 | 9.77 | 7.49 | 4.06 | 9.11 | 4.91 | 4.25 | 10.68 | 11.26 | 13.25 |
Net Debt/EBITDA |
2.93 | 1.84 | 1.63 | 0.89 | 1.82 | 1.48 | 0.67 | 1.41 | 2.89 | 3.61 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.09 | 0.08 | 0.06 | 0.00 | 0.00 | 0.14 | 0.03 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.87 | 0.90 | 0.73 | 0.84 | 0.94 | 0.82 | 0.96 | 0.29 | 0.76 | 1.09 |
Capex/Depreciation |
(0.91) | (1.91) | 1.41 | 3.73 | (4.00) | (0.22) | (0.02) | 0.49 | 0.00 | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (106.47%) | (48.08%) | (75.32%) | (122.74%) | (80.93%) | (58.81%) | (124.87%) | (1,371.79%) | (115.22%) | (33.69%) | |
| (41.05%) | (44.24%) | (66.28%) | (97.26%) | (66.09%) | (48.46%) | (92.58%) | (164.06%) | (43.78%) | (22.39%) | |
ROIC |
0.00% | (45,519.74%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(34.41%) | (54.24%) | (65.75%) | (133.70%) | (58.20%) | (79.00%) | (164.92%) | (109.45%) | (37.52%) | (21.58%) |
Average Days of Receivables |
95.82 | 215.84 | 28.16 | — | — | 15.87 | 58.77 | 0.00 | — | — |
Research and Development Expense of Revenue |
392.03% | 438.33% | 944.42% | 0.00% | 0.00% | 304.55% | 2,515.20% | 10,102.03% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
181.31% | 193.39% | 324.90% | 0.00% | 0.00% | 145.79% | 1,225.03% | 4,508.58% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
26.38% | 47.88% | 110.08% | 0.00% | 0.00% | 42.89% | 305.32% | 2,897.86% | 0.00% | 0.00% |
Graham Net Nets |
1.39 | 0.61 | 0.43 | — | — | 0.23 | 1.17 | 1.24 | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 14.94 | — | — |
Earnings Yield |
(184.68%) | (33.46%) | (28.44%) | — | — | (21.05%) | (239.79%) | (351.12%) | — | — |
Free Cash Flow Yield |
(42.57%) | (31.01%) | (20.91%) | — | — | (17.38%) | (225.89%) | (67.37%) | — | — |
Revenue per Share |
11.82 | 8.60 | 4.67 | 0.00 | 0.00 | 7.13 | 0.69 | 0.13 | 0.00 | 0.00 |
Operating CF per Share |
(48.10) | (40.68) | (38.65) | (51.40) | (35.49) | (20.43) | (23.77) | (14.49) | (3.35) | (2.64) |
Capex per Share |
(0.54) | (1.02) | (0.51) | (1.17) | (2.00) | (0.22) | (0.01) | 0.07 | 0.00 | 0.00 |
Free Cash Flow per Share |
(48.64) | (41.70) | (39.16) | (52.57) | (37.50) | (20.64) | (23.79) | (14.42) | (3.35) | (2.64) |
Cash per Share |
162.12 | 83.13 | 89.46 | 56.30 | 68.52 | 35.41 | 16.53 | 49.19 | 12.82 | 11.81 |
Shareholders Equity per Share |
160.75 | 83.19 | 80.96 | 47.01 | 65.50 | 31.92 | 14.92 | 26.68 | 11.01 | 11.17 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
160.75 | 83.19 | 80.96 | 47.01 | 65.50 | 31.92 | 14.92 | 26.68 | 11.01 | 11.17 |
Free Cash Flow |
(19.05) | (25.23) | (32.61) | (67.18) | (80.05) | (54.29) | (80.18) | (99.43) | (157.41) | (169.25) |
Working Capital |
62.46 | 49.36 | 66.43 | 56.15 | 133.35 | 78.75 | 47.60 | 309.55 | 554.41 | 719.10 |
Capital Expenditures |
(0.21) | (0.62) | (0.42) | (1.49) | (4.28) | (0.57) | (0.04) | 0.48 | — | — |
Net Current Asset Value |
62.33 | 49.25 | 66.36 | 51.40 | 128.00 | 72.91 | 41.42 | 183.69 | 517.79 | 715.24 |
EV/EBIT |
0.86 | 0.00 | 0.00 | — | — | 0.00 | 0.24 | 0.79 | — | — |
Capex to Sales |
0.05 | 0.12 | 0.11 | 0.00 | 0.00 | 0.03 | 0.02 | (0.54) | — | — |
Net Profit Margin |
(468.84%) | (523.27%) | (1,140.64%) | 0.00% | 0.00% | (351.14%) | (3,598.75%) | (38,238.15%) | 0.00% | 0.00% |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.39 | 0.38 | (0.29) | (0.17) | 0.19 | 0.56 | 0.51 | 0.00 | 0.00 | — |
Cash ROIC |
(15.37%) | (25.31%) | (23.40%) | (51.56%) | (28.46%) | (32.91%) | (78.63%) | (19.09%) | (14.04%) | (11.50%) |
Accounts Receivable Turnover |
3.18 | 2.42 | 2.30 | — | — | 33.61 | 3.91 | 0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
1.46 | 2.15 | 1.69 | — | — | 0.56 | 0.60 | — | — | — |
Average Payables |
0.17 | 0.28 | 0.53 | 1.91 | 2.70 | 2.79 | 2.00 | 0.79 | 0.78 | 4.79 |
Average Assets |
52.86 | 61.57 | 66.91 | 80.46 | 122.40 | 135.77 | 90.54 | 206.50 | 475.17 | 693.13 |
Average Common Equity |
20.38 | 56.65 | 58.88 | 63.75 | 99.96 | 111.89 | 67.12 | 24.70 | 180.54 | 460.70 |
Columns are period end dates